Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) was downgraded by stock analysts at ValuEngine from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

A number of other research analysts have also issued reports on ADMS. BidaskClub lowered shares of Adamas Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Thursday, August 17th. Noble Financial restated a “buy” rating and set a $33.00 price target on shares of Adamas Pharmaceuticals in a report on Friday, September 29th. Piper Jaffray Companies restated an “overweight” rating and set a $30.00 price target on shares of Adamas Pharmaceuticals in a report on Wednesday, September 20th. JMP Securities restated an “outperform” rating and set a $33.00 price target (up previously from $29.00) on shares of Adamas Pharmaceuticals in a report on Friday, August 25th. Finally, Mizuho restated a “buy” rating and set a $48.00 price target (up previously from $26.00) on shares of Adamas Pharmaceuticals in a report on Wednesday, September 13th. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. Adamas Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $39.50.

Shares of Adamas Pharmaceuticals (NASDAQ:ADMS) opened at 19.02 on Friday. Adamas Pharmaceuticals has a 12 month low of $12.10 and a 12 month high of $24.18. The firm’s market cap is $428.22 million. The stock’s 50 day moving average is $21.22 and its 200 day moving average is $17.73.

Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.81) by ($0.12). The company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.03 million. Adamas Pharmaceuticals’s revenue was down 90.9% compared to the same quarter last year. During the same period in the previous year, the business posted ($0.78) EPS. Analysts forecast that Adamas Pharmaceuticals will post ($3.77) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Adamas Pharmaceuticals, Inc. (ADMS) Stock Rating Lowered by ValuEngine” was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of U.S. & international copyright laws. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/10/15/adamas-pharmaceuticals-inc-adms-stock-rating-lowered-by-valuengine.html.

A number of institutional investors have recently added to or reduced their stakes in ADMS. Parametric Portfolio Associates LLC raised its holdings in Adamas Pharmaceuticals by 153.3% during the 1st quarter. Parametric Portfolio Associates LLC now owns 111,788 shares of the specialty pharmaceutical company’s stock worth $1,956,000 after purchasing an additional 67,654 shares during the last quarter. Vanguard Group Inc. raised its holdings in Adamas Pharmaceuticals by 10.3% during the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock worth $12,537,000 after purchasing an additional 66,825 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in Adamas Pharmaceuticals by 212.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock worth $1,066,000 after purchasing an additional 41,436 shares during the last quarter. Citadel Advisors LLC bought a new position in Adamas Pharmaceuticals during the 2nd quarter worth approximately $606,000. Finally, Bamco Inc. NY raised its holdings in Adamas Pharmaceuticals by 45.5% during the 2nd quarter. Bamco Inc. NY now owns 103,200 shares of the specialty pharmaceutical company’s stock worth $1,805,000 after purchasing an additional 32,272 shares during the last quarter. Hedge funds and other institutional investors own 69.16% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Stock Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.